iBio, Inc. cash flow to debt ratio of -436.26% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

iBio, Inc.'s free cash flow has increased -18.35% from $-18.76M last year to $-15.32M, signaling increasing performance

iBio, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

iBio, Inc.'s debt has decreased relative to shareholder equity from 0.21 last year to 0.03 today, signaling strengthened financials

iBio, Inc. has a net cash position, so leverage is healthy.

iBio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

iBio, Inc.'s profit margin has increased (-16.87%) in the last year from -11.07K% to -9.20K%, signaling increasing performance

iBio, Inc.'s short-term assets of $9.72M exceed its short-term liabilities of $6.11M

iBio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

iBio, Inc.'s return on equity of -53.86%, is lower than 15.00%, indicating bad performance

iBio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

iBio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

iBio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

iBio, Inc. has negative free cash flow, indicating cash burn

iBio, Inc.'s yearly earnings has increased -26.22% since last year from $-24.91M to $-18.38M, signaling increasing performance

iBio, Inc.'s yearly revenue has increased 77.78% since last year from $225.00K to $400.00K, signaling increasing performance

ROIC -30.00% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

iBio, Inc.'s 3-year revenue CAGR of -40.34% is negative, indicating declining revenue over the past 3 years

iBio, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

iBio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

iBio, Inc. has insufficient data to evaluate this check.

iBio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

iBio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

iBio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

iBio, Inc. has insufficient data to evaluate this check.

iBio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

iBio, Inc. has a price-to-book ratio of 2.16x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

iBio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue